Changes in skeletal muscle gene expression following clenbuterol administration

Spurlock, Diane M; McDaneld, Tara G; McIntyre, Lauren M

doi:10.1186/1471-2164-7-320

BMC Genomics

Table 2 Selected^a genes of interest.

From: Changes in skeletal muscle gene expression following clenbuterol administration

AffyID	Gene Name	Rank^b	P-value^c	Change 24 h^d	Change 10 D^e	Change 10 D/24 h^f
1437711_x_at	Ornithine decarboxylase, structural	70	0.000372006	1.68	1.32	-1.28
1452114_s_at	Insulin-like growth factor binding protein 5	83	0.000505398	-4.01	-1.52	2.63
1422648_at	Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2	84	0.000505714	-1.81	n/s	2.23
1424112_at	Insulin-like growth factor 2 receptor	95	0.000653571	-1.58	-1.53	n/s
1448166_a_at	Proteasome (prosome, macropain) subunit, beta type 1	96	0.000658819	1.39	1.23	-1.13
1420971_at	Ubiquitin protein ligase E3 component n-recognin 1	169	0.001652967	n/s	1.75	2.12
1449547_at	Ankyrin repeat and SOCS box-containing protein 14	218	0.002452054	-2.64	n/s	2.08
1449940_a_at	Eukaryotic translation initiation factor 2B, subunit 4 delta	268	0.003245646	1.91	n/s	-1.65
1421027_a_at	Myocyte enhancer factor 2C	294	0.003678395	-1.43	n/s	1.58
1451422_at	Myosin XVIIIa	301	0.003765249	1.68	1.38	-1.22
1448171_at	Seven in absentia 2	342	0.004599517	4.39	2.57	-1.71
1451982_at	Mitogen activated protein kinase kinase 4	363	0.004917906	1.44	n/s	-1.23
1426850_a_at	Mitogen activated protein kinase kinase 6	393	0.00551809	-2.64	n/s	2.51
1448990_a_at	Myosin IB	405	0.005781979	-1.52	n/s	1.63
1423449_a_at	Actinin alpha 4	422	0.006130447	1.32	n/s	-1.69
1454664_a_at	Eukaryotic translation initiation factor 5	450	0.006788818	1.63	n/s	-1.79
1435787_at	Protein phosphatase 1 (formerly 2C)-like	454	0.006890512	-1.79	n/s	1.49
1451136_a_at	Eukaryotic translation initiation factor 2B, subunit 2 beta	455	0.006894746	1.46	n/s	-1.54
1419391_at	Myogenin	460	0.007033703	4.07	n/s	-3.61
1424268_at	Spermine oxidase	473	0.007450143	-2.54	n/s	2.89
1426833_at	Eukaryotic translation initiation factor 4 gamma, 3	569	0.009710166	-1.41	n/s	1.57

^aSelected genes of interest that did not meet the 10% FDR criteria, but showed evidence of differential expression (P < 0.01) are presented and discussed in the text.
^bRank of P-value based on analysis of variance of all expressed genes (n = 22,605)
^cP-value resulting from analysis of variance. Model included treatment (control, 24 h, and 10 D clenbuterol administration) as a fixed effect. False discovery rates of 5, 10, and 20% correspond to P-values of 0.0000082, 0.00025, and 0.0012, respectively.
^dFold change in mRNA abundance for 24 h clenbuterol treatment relative to control. A positive fold change indicates increased mRNA abundance in 24 h treatment relative to control, a negative fold change indicates decreased mRNA abundance in 24 h treatment relative to control, and n/s indicates no significant difference between 24 h treatment and control (contrast P-value > 0.05)
^eFold change in mRNA abundance for 10 D clenbuterol treatment relative to control. A positive fold change indicates increased mRNA abundance in 10 D treatment relative to control, a negative fold change indicates decreased mRNA abundance in 10 D treatment relative to control, and n/s indicates no significant difference between 10 D treatment and control (contrast P-value > 0.05)
^fFold change in mRNA abundance for 24 h clenbuterol treatment relative to 10 D clenbuterol treatment. A positive fold change indicates increased mRNA abundance in 10 D treatment relative to 24 h treatment, a negative fold change indicates decreased mRNA abundance in 10 D treatment relative to 24 h treatment, and n/s indicates no significant difference between 10 D treatment and 24 h treatment (contrast P-value > 0.05)

Back to article page

ISSN: 1471-2164

Contact us

Submission enquiries: bmcgenomics@biomedcentral.com
General enquiries: ORSupport@springernature.com